Biotechnology
Samsung Biologics Unveils Virtual Exhibition Hall to Digitally Connect with Clients at BIO 2020
SONGDO, South Korea, June 8, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced the launch of a Virtual Exhibition Hall, coinciding with the opening of BIO Digital 2020 week. As the biopharmaceutical industry's largest event, BIO International Convention brings together over 17,000 indu...
2020-06-08 19:00
1826
Healios Successfully Establishes Proprietary Universal Donor Cell Research Line
TOKYO, June 5, 2020 /PRNewswire/ -- Healios K.K. (hereinafter "the Company"; TSE: 4593),Japan's leading clinical-stage biotechnology company, has been creating Universal Donor Cells (UDCs), which are next-generation iPS cells created with gene-editing technology to engineer a low risk of immune r...
2020-06-05 13:00
2158
PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas
DAEJEON, South Korea, June 3, 2020 /PRNewswire/ -- PharmAbcine (KOSDAQ: 208340), a clinical-stage biotechnology company, announced today that the company entered into a license agreement with Wincal Biopharm ("Wincal"), a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the c...
2020-06-04 00:00
1524
New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis
Key Highlights * TGA has granted provisional designation for new drug Lurbinectedin based on encouraging Phase 2 results and high unmet medical need * A marketing application has now been accepted by the TGA under provisional evaluation pathway * Lurbinectedin has received priority review u...
2020-06-03 14:30
1459
Firmenich Appoints Boet Brinkgreve as President Ingredients
GENEVA, June 2, 2020 /PRNewswire/ -- In order to strengthen Firmenich industry leadership in ingredients and drive a new era of excellence, Firmenich, has appointed Boet Brinkgreve to President of Ingredients, effectiveJune 1st, 2020. Boet will continue to report directly to Firmenich CEO,Gilbert...
2020-06-02 23:41
1886
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced ...
2020-06-01 07:30
1865
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the research results of TY...
2020-06-01 07:30
1929
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of TYVYT® (sin...
2020-06-01 07:30
2635
(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
SUZHOU, China and ROCKVILLE, Md., May 31, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company presented fo...
2020-05-31 20:00
2334
I-Mab Announces Upcoming Participation at June Conferences
SHANGHAI and GAITHERSBURG, Md., May 29, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical ...
2020-05-29 20:00
6168
Seaweed Extract Offers Hope for Influenza A
CAMBRIDGE, Australia, May 28, 2020 /PRNewswire/ -- Australian scientists have revealed that a natural compound found in seaweed may reduce the effects of severe cases of Influenza A. Fucoidan is a highly bioactive compound found naturally in brown seaweed and well known for its diverse therapeu...
2020-05-28 15:30
1183
IntegriCulture Inc. Closes Series A Fundraising Round Led by Beyond Next Ventures at JPY800 Million
TOKYO, May 28, 2020 /PRNewswire/ -- IntegriCulture Inc. has completed a Series A fundraising round ofJPY800 million (USD7.4 million) backed by Beyond Next Ventures, NH Foods, AgFunder and other investors. The cumulative amount raised stands aboutJPY1.1 billion (USD10.2 million). (Logo: https://...
2020-05-28 13:00
2152
Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies
SUZHOU, China, May 27, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery,development and manufacturing of antibody-based therapeutics, announced today results reported for the first time from a Phase 1...
2020-05-27 23:00
1231
Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets
AMBLER, Pa., May 25, 2020 /PRNewswire/ -- Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's Du...
2020-05-25 22:00
1553
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
LONDON and SONGDO, South Korea, May 21, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK's innovative biopharmaceutical therapies. Under the terms of th...
2020-05-22 07:11
6464
Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II
SUZHOU, China, May 21, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing, today announced that it will present preclinical data of TST001, a humanized Claudin 18.2 (CLDN18.2) monoclonal ...
2020-05-21 23:00
1614
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction
BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today declared that Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan"), China Biolog...
2020-05-21 04:45
11512
China Biologic Reports Financial Results for the First Quarter of 2020
BEIJING, May 20, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the first quarter of 2020. First Quarter ...
2020-05-21 04:30
10677
VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
AUSTIN, Texas, May 20, 2020 /PRNewswire/ -- VolitionRx Limited
2020-05-20 20:45
10874
WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platform
PHILADELPHIA, May 18, 2020 /PRNewswire/ -- WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advanced therapies industry, announced today the expansion of its service capabilities to offer a fully int...
2020-05-18 21:00
1997
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7120
